[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @DrRishabhOnco Dr Rishabh Jain Dr Rishabh Jain posts on X about matterhorn, combo, iii, cns the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours. ### Engagements: XXX [#](/creator/twitter::1667191746185551873/interactions)  - X Week XXXXXX +46% - X Month XXXXXXX +72% - X Months XXXXXXX +200,004% ### Mentions: XX [#](/creator/twitter::1667191746185551873/posts_active)  - X Week XX +29% - X Month XX +78% - X Months XXX +10,000% ### Followers: XXXXX [#](/creator/twitter::1667191746185551873/followers)  - X Week XXXXX +8.70% - X Month XXXXX +122% - X Months XXXXX +25,677% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1667191746185551873/influencer_rank)  ### Social Influence [#](/creator/twitter::1667191746185551873/influence) --- **Social category influence** [travel destinations](/list/travel-destinations) XX% [currencies](/list/currencies) XXX% [countries](/list/countries) XXX% **Social topic influence** [matterhorn](/topic/matterhorn) #74, [combo](/topic/combo) 2.5%, [iii](/topic/iii) 2.5%, [cns](/topic/cns) 2.5%, [snapshot](/topic/snapshot) 2.5%, [bold](/topic/bold) 2.5%, [taiwan](/topic/taiwan) 2.5%, [dx](/topic/dx) XXX% **Top accounts mentioned or mentioned by** [@oncoalert](/creator/undefined) [@esmoopen](/creator/undefined) [@myesmo](/creator/undefined) [@asco](/creator/undefined) [@jcoasco](/creator/undefined) [@dfcibreastonc](/creator/undefined) [@erictopol](/creator/undefined) [@elonmusk](/creator/undefined) [@drpatsoonshiong](/creator/undefined) [@viveksubbiah](/creator/undefined) [@cruk](/creator/undefined) [@neerajresearch](/creator/undefined) [@jamaonc](/creator/undefined) [@jcoopjournal](/creator/undefined) [@lancetoncol](/creator/undefined) [@nobelprize](/creator/undefined) [@gastriccancerj](/creator/undefined) [@canceracs](/creator/undefined) [@cancerjrnl](/creator/undefined) [@scireports](/creator/undefined) ### Top Social Posts [#](/creator/twitter::1667191746185551873/posts) --- Top posts by engagements in the last XX hours "🔥 Liver Arsenal for Colorectal Cancer - who rules 2025 🎯 Resection still reigns but new contenders are rising fast. Heres how every liver-directed therapy stacks up 👇 🩺 X Resection & Ablation Gold standard if R0 & FLR adequate MWA RFA 🔥 COLLISION Trial 2025: MWA non-inferior to resection (5-yr OS XX% vs 58%) Combo resection + ablation hepatic failure same DFS/OS 💉 X Hepatic Artery Infusion (HAI) Targets arterial tumor flow high local FUDR dose 10-yr OS XX% vs XX% with adjuvant HAI Conversion to resection 3050 % 🔬 PUMP Trial ongoing (NCT05863195) ☢ X Trans-Arterial Radioembolization" [X Link](https://x.com/DrRishabhOnco/status/1977104436964044884) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-11T20:10Z 3385 followers, 13.4K engagements "🎯 ALEX delivers the long game - 1L Alectinib hits 6.5-year median OS in ALK NSCLC 🫁 #ESMO25 💊 Arms 🔹 Alectinib XXX mg BID 🔹 Crizotinib XXX mg BID 📊 Final Results OS : XXXX mo vs XXXX mo (HR XXXX 0.561.08) 🎯 DoR : XXXX mo vs XXXX mo (HR XXXX 0.300.56) 📈 PFS (prior) : XXXX mo vs XXXX mo 🧠 CNS benefit : consistent irrespective of baseline mets ⚕ Safety 💥 Grade X AEs : XX % vs XX % Median Tx duration : XXXX vs XXXX mo 🩺 Profile consistent with previous reports ✅ Takeaway 🕰 Durable OS XXX yrs + deep CNS control = Alectinib remains the global 1L standard for ALK NSCLC. #OncoTwitter" [X Link](https://x.com/DrRishabhOnco/status/1979119793216327858) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-17T09:38Z 3385 followers, 4530 engagements "🎯 ALEX delivers the long game Final 7-year update at #ESMO25 🧬 📍 Phase III ALK+ advanced NSCLC 💊 Alectinib (600 mg BID) vs Crizotinib (250 mg BID) 🧩 Results: Median OS XXXX mo vs XXXX mo (HR XXXX 0.561.08) 7-yr OS rate XXXX % vs XXXX % PFS (earlier readout): XXXX mo vs XXXX mo CNS benefit consistent across subgroups ⚕ Safety: All-grade AEs XX % G3-5 AEs XX % (balanced) Most common: bilirubin (alectinib) ALT (crizotinib) ✅ Takeaway: Durable survival cleaner toxicity and lasting CNS control - alectinib remains the benchmark 1L ALK TKI. #OncoTwitter #MedTwitter #LungCancer #ESMO25" [X Link](https://x.com/DrRishabhOnco/status/1979250962071196060) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-17T18:19Z 3352 followers, 2714 engagements "🔥 From ineligible ➜ unbeatable: EV + Pembro raises the bar in MIBC 📍 KEYNOTE-905 / EV-303 (Phase III) Peri-op EV + Pembrolizumab vs Observation in cis-ineligible or declining MIBC 🎯 Primary EFS (BICR): HR XXXX (95% CI 0.280.57) P XXXXXX 💪 Secondary OS: HR XXXX (95% CI 0.330.74) P = XXXXXX 24-mo EFS: XXXX % vs XXXX % 24-mo OS: XXXX % vs XXXX % 👥 n = XXX Median age XX y XX % cis-ineligible ✅ EV + Pembro sets a new peri-operative benchmark for patients without cisplatin options. #ESMO25 #OncoTwitter #BladderCancer @OncoAlert @myesmo @esmo_open @JCO_ASCO" [X Link](https://x.com/DrRishabhOnco/status/1979587662127538626) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-18T16:37Z 3351 followers, 1783 engagements "#ESMO25 X Days to go Here are my top X GI trials 🎤 MATTERHORN (LBA81) ✨ Durvalumab + FLOT in resectable gastric/GEJ adenocarcinoma. 🎸 CheckMate 8HW (LBA29) ✨ Nivolumab Ipilimumab in MSI-H/dMMR mCRC. 🥁Imbrave152 / SKYSCRAPER-14 (LBA50) ✨ Tiragolumab + Atezolizumab + Bevacizumab in 1L HCC. 🎸 DYNAMIC-III (LBA9) ✨ ctDNA-guided adjuvant chemo in stage III CRC. 👉 Whats yours PS- @elonmusk grok is amazing #OncoTwitter #GastroOncology #GIcancer #LiverCancer #ColorectalCancer #ESMO25 @OncoAlert @myesmo @esmo_open @JCO_ASCO @ASCO @VivekSubbiah" [X Link](https://x.com/DrRishabhOnco/status/1978881121506206047) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-16T17:49Z 3368 followers, 1136 engagements "🎯 MATTERHORN delivers: Durvalumab + FLOT lifts survival in resectable gastric / GEJ adenocarcinoma 🔥 #ESMO25 Phase X n XXX D 1500 mg Q4W + FLOT vs Placebo + FLOT ✅ Improved EFS & OS (HR XXXX XX % CI 0.63-0.96 p = 0.021) 💪 Benefit seen irrespective of PD-L1 status (1 % & X %) 🧩 Higher ypN-neg rates (58 % vs XX %) + strong path response benefit 📈 EFS gain across pCR MPR & any path response 💡 Takeaway: Durvalumab + FLOT not only boosts EFS but achieves a clinically meaningful OS improvement - a new peri-operative standard for G/GEJ adenocarcinoma at #ESMO25 🚀 #OncoTwitter #GastricCancer" [X Link](https://x.com/DrRishabhOnco/status/1979054366276620378) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-17T05:18Z 3368 followers, 7037 engagements "🧬 Aging & Immunity: Time to Update Normal Lymphocyte Ranges A massive UK dataset (45780 FBCs) reveals ALC falls X% per decade yet labs still use a fixed adult cutoff (1.04.0 10/L) 🧪 ➡ Mislabels up to X in X elderly as lymphopenic 👩⚕ Proposed fix: age-specific reference intervals 1829 yrs Lower 2.5th = XXXX 10/L XX yrs Lower 2.5th = XXXX 10/L 🧓🏽 Adjusting by age slashes false-positive lymphopenia rates & patient anxiety. 🧠 Takeaway: Like pediatric labs adult hematology must go age-smart. 📊 Precision begins with proper reference intervals. 📖 Elmahdi et al. Am J Hematol 2025. 🔗 #ESMO25" [X Link](https://x.com/DrRishabhOnco/status/1979978202056724735) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-19T18:29Z 3371 followers, 2419 engagements "🦋 PHENIX rises lymphadenectomy falls 💎 NEJM 2025 landmark: Sentinel-node biopsy alone is non-inferior to full lymphadenectomy in early cervical cancer with fewer complications and zero nodal recurrences 🔥 👩⚕ PHENIX Trial Phase X n = XXX Stage IA1IIA1 Median FU XX mo 💊 Trial Arms 🔹 Sentinel-node biopsy only 🔹 Sentinel-node + bilateral lymphadenectomy 📊 Key Results ✅ 3-yr DFS: XXXX % vs XXXX % 🟢 Non-inferior (P 0.001) 💀 3-yr CSS: XXXX % vs XXXX % HR XXXX (0.150.95) 🧭 Retroperitoneal recurrence: X % vs XXX % 💧 Lymphedema: XXX % vs XXXX % (P 0.001) 🫧 Lymphocyst: XXX % vs XX % (P" [X Link](https://x.com/DrRishabhOnco/status/1978817065483112553) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-16T13:35Z 3372 followers, 2373 engagements "🌍 Cancer deaths will nearly double by mid-century are we ready 🚨 GBD 2023 update (Lancet) 👥 2023 snapshot 18.5M new cases 10.4M deaths 271M DALYs XX% of deaths preventable risks (tobacco alcohol diet infections) 📊 Trends 19902023 Cases XXX% Deaths XX% DALYs XX% Age-std mortality XX% 🔮 Forecast 2050 30.5M new cases 18.6M deaths Heaviest rise in LMICs (90% vs XX% in HICs) 💡 Takeaway Survival gains are real ✅ but nowhere near enough to meet SDG XXX ( premature NCD mortality by 2030). 📖 GBD 2023 Cancer Collaborators. Lancet. 2025. 🔗 #OncoTwitter #MedTwitter #CancerEpidemiology" [X Link](https://x.com/DrRishabhOnco/status/1971179043577004219) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-09-25T11:44Z 3381 followers, 1604 engagements "🎶 The Fab X of #ESMO25 GI Trials 🎶 (The Beatles of GI oncology) 👑 Paul MATTERHORN (LBA81) ✨ The melodic leader 🎤 ➡ Durvalumab + FLOT in resectable gastric/GEJ adenocarcinoma. 🎶 Setting the rhythm for peri-operative immunotherapy. 🎸 John CheckMate 8HW (LBA29) ✨ The bold visionary 🎸 ➡ Nivolumab Ipilimumab in MSI-H/dMMR mCRC. 🎶 Still redefining the long-term harmony of immunotherapy. 🥁 Ringo Imbrave152 / SKYSCRAPER-14 (LBA50) ✨ The steady backbone 🥁 ➡ Tiragolumab + Atezolizumab + Bevacizumab in 1L HCC. 🎶 Keeping the beat for triplet IO therapy in hepatocellular carcinoma. 🎹 George" [X Link](https://x.com/DrRishabhOnco/status/1977382707442385354) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-12T14:35Z 3382 followers, 7170 engagements "LEAP-014 (LBA79) #ESMO25 Does adding lenvatinib to pembrolizumab + chemo help in 1L metastatic ESCC Short answer: No OS gain at IA2. 🧪 Trial essentials Phase III Untreated mESCC n=850 CPS 1: XX% (CPS 10: 65%) Chemo backbone: FP / mFOLFOX6 / TP (per region) 💊 Arms 🔹 Lenvatinib + Pembrolizumab + Chemo (induction len XX mg QD + pembro Q6W maintenance) 🔹 Pembrolizumab + Chemo 📊 Key results (IA2; data cutoff May X 2025) 🕒 OS: XXXX vs XXXX mo HR XXXX (95% CI 0.771.10) - NS PFS: XXX vs XXX mo HR XXXX (95% CI 0.751.04) - nominal p=0.075 (not formally tested) 🎯 ORR: XX% vs XX% DoR: XXX vs 6.8" [X Link](https://x.com/DrRishabhOnco/status/1979111268985270729) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-17T09:04Z 3381 followers, 3145 engagements "🎯 Dato-DXd doubles ORR & improves survival in 1L TNBC 💪🩸 #TROPIONBreast02 Phase III 1L inoperable/metastatic TNBC 💊 Arms: 🔹 Dato-DXd X mg/kg Q3W (n=323) 🔹 Investigators choice chemo (ICC n=321) 📈 Results (BICR): ORR: XXXX% vs XXXX% ( +33%) CR: X% vs XXX% Median PFS: XXXX mo vs XXX mo (HR 0.57) Median OS: XXXX mo vs XXXX mo (HR 0.79) ✅ Takeaway: Dato-DXd significantly improved PFS (+5.3 mo) and OS (+5.0 mo) vs chemo #ESMO25 #OncoTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open @AnnOncology" [X Link](https://x.com/DrRishabhOnco/status/1979828266845220904) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-19T08:33Z 3383 followers, 1188 engagements "🚀 From local shot ➡ systemic fight: Intratumoral CD40 agonist sparks tumor immunity 🔥 🧬 Cancer Cell Oct 2025 Phase X (NCT04059588) XX pts with metastatic solid tumors 💊 Therapy: Fc-engineered anti-CD40 agonistic antibody 2141-V11 (i.t.) 🎯 Enhances FcRIIB binding better CD40 cross-linking & immune activation 📊 Results ✅ Safe no DLTs up to XX mg dose 💪 Responses in 6/12 pts (2 CR melanoma & HR+ breast cancer) 🌍 Abscopal effect: regression of non-injected lesions 🧫 Mechanism: formation of tertiary lymphoid structures (TLS) local CD8 T-cell priming 🧠 Mouse model: TLS formed long-term" [X Link](https://x.com/DrRishabhOnco/status/1978461861634068721) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-15T14:04Z 3383 followers, 1459 engagements "🔥 Chemo-IO climbs the MATTERHORN Durvalumab + FLOT ⛰ lifts peri-operative gastric/GEJ cancer outcomes at #ESMO25 ✅ OS HR XXXX (p = 0.021) ✅ Higher pCR & EFS gains across PD-L1 + node-positive & diffuse subgroups 💪 Median OS NR in both arms but curves clearly part ways 📊 Durvalumab + FLOT sets a new standard for fit resectable disease. #OncoTwitter #GastricCancer #Immunotherapy #ESMO25 @OncoAlert @myesmo @esmo_open" [X Link](https://x.com/DrRishabhOnco/status/1979266508368044351) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-17T19:21Z 3382 followers, 3168 engagements "🎯 HARMONi-6 delivers new hope in 1L advanced squamous #NSCLC 🫁 📍 Phase III n=532 1L Stage IIIBIV sqNSCLC 💊 Arms: 🔹 Ivonescimab + chemo (20 mg/kg Q3W) 🔹 Tislelizumab + chemo (200 mg Q3W) Followed by monotherapy maintenance 📈 Results: PFS: XXXX mo vs XXX mo (HR XXXX 0.460.78 p0.0001) PD-L1 1%: XXX vs XXX mo (HR 0.55) PD-L1 1%: XXXX vs XXX mo (HR 0.66) ✅ Consistent benefit across subgroups ⚕ Safety: SAE XXXX % vs XXXX % Grade X hemorrhagic events XXX % vs XXX % 🧩 Takeaway: Ivonescimab-chemo shows superior PFS vs tislelizumab-chemo - emerging as a potential new 1L standard for advanced" [X Link](https://x.com/DrRishabhOnco/status/1979702070182908180) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-19T00:12Z 3383 followers, 4687 engagements "🚭 Lung Cancer in Never-Smokers Yes and its rising fast 🫁📈 🧩 Key facts from Murphy et al. JAMA 2025: 15-20% of all lung cancers occur in never-smokers Median age at dx XX y (younger than smokers XX y) 🌏 Rising incidence esp in Asian women (up to XX% cases in Taiwan) 🔬 60-80% adenocarcinoma ⚠ Major risks: passive smoke radon PM2.5 pollution asbestos family hx 🧠 Genomics: 🧬EGFR (43%) & ALK (12%) vs XX% & X% in smokers 🧬Low TMB (03 mut/Mb vs 030) = poorer IO response 💊 Therapy: Adjuvant osimertinib 5-yr OS XX% vs XX% (placebo) Alectinib DFS XX% vs XX% Immunotherapy alone 🪫 limited" [X Link](https://x.com/DrRishabhOnco/status/1980658346203213866) [@DrRishabhOnco](/creator/x/DrRishabhOnco) 2025-10-21T15:32Z 3385 followers, 6188 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@DrRishabhOnco Dr Rishabh Jain
Dr Rishabh Jain posts on X about matterhorn, combo, iii, cns the most. They currently have XXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXXX +46%
- X Month XXXXXXX +72%
- X Months XXXXXXX +200,004%
Mentions: XX #
- X Week XX +29%
- X Month XX +78%
- X Months XXX +10,000%
Followers: XXXXX #
- X Week XXXXX +8.70%
- X Month XXXXX +122%
- X Months XXXXX +25,677%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence travel destinations XX% currencies XXX% countries XXX%
Social topic influence matterhorn #74, combo 2.5%, iii 2.5%, cns 2.5%, snapshot 2.5%, bold 2.5%, taiwan 2.5%, dx XXX%
Top accounts mentioned or mentioned by @oncoalert @esmoopen @myesmo @asco @jcoasco @dfcibreastonc @erictopol @elonmusk @drpatsoonshiong @viveksubbiah @cruk @neerajresearch @jamaonc @jcoopjournal @lancetoncol @nobelprize @gastriccancerj @canceracs @cancerjrnl @scireports
Top Social Posts #
Top posts by engagements in the last XX hours
"🔥 Liver Arsenal for Colorectal Cancer - who rules 2025 🎯 Resection still reigns but new contenders are rising fast. Heres how every liver-directed therapy stacks up 👇 🩺 X Resection & Ablation Gold standard if R0 & FLR adequate MWA RFA 🔥 COLLISION Trial 2025: MWA non-inferior to resection (5-yr OS XX% vs 58%) Combo resection + ablation hepatic failure same DFS/OS 💉 X Hepatic Artery Infusion (HAI) Targets arterial tumor flow high local FUDR dose 10-yr OS XX% vs XX% with adjuvant HAI Conversion to resection 3050 % 🔬 PUMP Trial ongoing (NCT05863195) ☢ X Trans-Arterial Radioembolization"
X Link @DrRishabhOnco 2025-10-11T20:10Z 3385 followers, 13.4K engagements
"🎯 ALEX delivers the long game - 1L Alectinib hits 6.5-year median OS in ALK NSCLC 🫁 #ESMO25 💊 Arms 🔹 Alectinib XXX mg BID 🔹 Crizotinib XXX mg BID 📊 Final Results OS : XXXX mo vs XXXX mo (HR XXXX 0.561.08) 🎯 DoR : XXXX mo vs XXXX mo (HR XXXX 0.300.56) 📈 PFS (prior) : XXXX mo vs XXXX mo 🧠 CNS benefit : consistent irrespective of baseline mets ⚕ Safety 💥 Grade X AEs : XX % vs XX % Median Tx duration : XXXX vs XXXX mo 🩺 Profile consistent with previous reports ✅ Takeaway 🕰 Durable OS XXX yrs + deep CNS control = Alectinib remains the global 1L standard for ALK NSCLC. #OncoTwitter"
X Link @DrRishabhOnco 2025-10-17T09:38Z 3385 followers, 4530 engagements
"🎯 ALEX delivers the long game Final 7-year update at #ESMO25 🧬 📍 Phase III ALK+ advanced NSCLC 💊 Alectinib (600 mg BID) vs Crizotinib (250 mg BID) 🧩 Results: Median OS XXXX mo vs XXXX mo (HR XXXX 0.561.08) 7-yr OS rate XXXX % vs XXXX % PFS (earlier readout): XXXX mo vs XXXX mo CNS benefit consistent across subgroups ⚕ Safety: All-grade AEs XX % G3-5 AEs XX % (balanced) Most common: bilirubin (alectinib) ALT (crizotinib) ✅ Takeaway: Durable survival cleaner toxicity and lasting CNS control - alectinib remains the benchmark 1L ALK TKI. #OncoTwitter #MedTwitter #LungCancer #ESMO25"
X Link @DrRishabhOnco 2025-10-17T18:19Z 3352 followers, 2714 engagements
"🔥 From ineligible ➜ unbeatable: EV + Pembro raises the bar in MIBC 📍 KEYNOTE-905 / EV-303 (Phase III) Peri-op EV + Pembrolizumab vs Observation in cis-ineligible or declining MIBC 🎯 Primary EFS (BICR): HR XXXX (95% CI 0.280.57) P XXXXXX 💪 Secondary OS: HR XXXX (95% CI 0.330.74) P = XXXXXX 24-mo EFS: XXXX % vs XXXX % 24-mo OS: XXXX % vs XXXX % 👥 n = XXX Median age XX y XX % cis-ineligible ✅ EV + Pembro sets a new peri-operative benchmark for patients without cisplatin options. #ESMO25 #OncoTwitter #BladderCancer @OncoAlert @myesmo @esmo_open @JCO_ASCO"
X Link @DrRishabhOnco 2025-10-18T16:37Z 3351 followers, 1783 engagements
"#ESMO25 X Days to go Here are my top X GI trials 🎤 MATTERHORN (LBA81) ✨ Durvalumab + FLOT in resectable gastric/GEJ adenocarcinoma. 🎸 CheckMate 8HW (LBA29) ✨ Nivolumab Ipilimumab in MSI-H/dMMR mCRC. 🥁Imbrave152 / SKYSCRAPER-14 (LBA50) ✨ Tiragolumab + Atezolizumab + Bevacizumab in 1L HCC. 🎸 DYNAMIC-III (LBA9) ✨ ctDNA-guided adjuvant chemo in stage III CRC. 👉 Whats yours PS- @elonmusk grok is amazing #OncoTwitter #GastroOncology #GIcancer #LiverCancer #ColorectalCancer #ESMO25 @OncoAlert @myesmo @esmo_open @JCO_ASCO @ASCO @VivekSubbiah"
X Link @DrRishabhOnco 2025-10-16T17:49Z 3368 followers, 1136 engagements
"🎯 MATTERHORN delivers: Durvalumab + FLOT lifts survival in resectable gastric / GEJ adenocarcinoma 🔥 #ESMO25 Phase X n XXX D 1500 mg Q4W + FLOT vs Placebo + FLOT ✅ Improved EFS & OS (HR XXXX XX % CI 0.63-0.96 p = 0.021) 💪 Benefit seen irrespective of PD-L1 status (1 % & X %) 🧩 Higher ypN-neg rates (58 % vs XX %) + strong path response benefit 📈 EFS gain across pCR MPR & any path response 💡 Takeaway: Durvalumab + FLOT not only boosts EFS but achieves a clinically meaningful OS improvement - a new peri-operative standard for G/GEJ adenocarcinoma at #ESMO25 🚀 #OncoTwitter #GastricCancer"
X Link @DrRishabhOnco 2025-10-17T05:18Z 3368 followers, 7037 engagements
"🧬 Aging & Immunity: Time to Update Normal Lymphocyte Ranges A massive UK dataset (45780 FBCs) reveals ALC falls X% per decade yet labs still use a fixed adult cutoff (1.04.0 10/L) 🧪 ➡ Mislabels up to X in X elderly as lymphopenic 👩⚕ Proposed fix: age-specific reference intervals 1829 yrs Lower 2.5th = XXXX 10/L XX yrs Lower 2.5th = XXXX 10/L 🧓🏽 Adjusting by age slashes false-positive lymphopenia rates & patient anxiety. 🧠 Takeaway: Like pediatric labs adult hematology must go age-smart. 📊 Precision begins with proper reference intervals. 📖 Elmahdi et al. Am J Hematol 2025. 🔗 #ESMO25"
X Link @DrRishabhOnco 2025-10-19T18:29Z 3371 followers, 2419 engagements
"🦋 PHENIX rises lymphadenectomy falls 💎 NEJM 2025 landmark: Sentinel-node biopsy alone is non-inferior to full lymphadenectomy in early cervical cancer with fewer complications and zero nodal recurrences 🔥 👩⚕ PHENIX Trial Phase X n = XXX Stage IA1IIA1 Median FU XX mo 💊 Trial Arms 🔹 Sentinel-node biopsy only 🔹 Sentinel-node + bilateral lymphadenectomy 📊 Key Results ✅ 3-yr DFS: XXXX % vs XXXX % 🟢 Non-inferior (P 0.001) 💀 3-yr CSS: XXXX % vs XXXX % HR XXXX (0.150.95) 🧭 Retroperitoneal recurrence: X % vs XXX % 💧 Lymphedema: XXX % vs XXXX % (P 0.001) 🫧 Lymphocyst: XXX % vs XX % (P"
X Link @DrRishabhOnco 2025-10-16T13:35Z 3372 followers, 2373 engagements
"🌍 Cancer deaths will nearly double by mid-century are we ready 🚨 GBD 2023 update (Lancet) 👥 2023 snapshot 18.5M new cases 10.4M deaths 271M DALYs XX% of deaths preventable risks (tobacco alcohol diet infections) 📊 Trends 19902023 Cases XXX% Deaths XX% DALYs XX% Age-std mortality XX% 🔮 Forecast 2050 30.5M new cases 18.6M deaths Heaviest rise in LMICs (90% vs XX% in HICs) 💡 Takeaway Survival gains are real ✅ but nowhere near enough to meet SDG XXX ( premature NCD mortality by 2030). 📖 GBD 2023 Cancer Collaborators. Lancet. 2025. 🔗 #OncoTwitter #MedTwitter #CancerEpidemiology"
X Link @DrRishabhOnco 2025-09-25T11:44Z 3381 followers, 1604 engagements
"🎶 The Fab X of #ESMO25 GI Trials 🎶 (The Beatles of GI oncology) 👑 Paul MATTERHORN (LBA81) ✨ The melodic leader 🎤 ➡ Durvalumab + FLOT in resectable gastric/GEJ adenocarcinoma. 🎶 Setting the rhythm for peri-operative immunotherapy. 🎸 John CheckMate 8HW (LBA29) ✨ The bold visionary 🎸 ➡ Nivolumab Ipilimumab in MSI-H/dMMR mCRC. 🎶 Still redefining the long-term harmony of immunotherapy. 🥁 Ringo Imbrave152 / SKYSCRAPER-14 (LBA50) ✨ The steady backbone 🥁 ➡ Tiragolumab + Atezolizumab + Bevacizumab in 1L HCC. 🎶 Keeping the beat for triplet IO therapy in hepatocellular carcinoma. 🎹 George"
X Link @DrRishabhOnco 2025-10-12T14:35Z 3382 followers, 7170 engagements
"LEAP-014 (LBA79) #ESMO25 Does adding lenvatinib to pembrolizumab + chemo help in 1L metastatic ESCC Short answer: No OS gain at IA2. 🧪 Trial essentials Phase III Untreated mESCC n=850 CPS 1: XX% (CPS 10: 65%) Chemo backbone: FP / mFOLFOX6 / TP (per region) 💊 Arms 🔹 Lenvatinib + Pembrolizumab + Chemo (induction len XX mg QD + pembro Q6W maintenance) 🔹 Pembrolizumab + Chemo 📊 Key results (IA2; data cutoff May X 2025) 🕒 OS: XXXX vs XXXX mo HR XXXX (95% CI 0.771.10) - NS PFS: XXX vs XXX mo HR XXXX (95% CI 0.751.04) - nominal p=0.075 (not formally tested) 🎯 ORR: XX% vs XX% DoR: XXX vs 6.8"
X Link @DrRishabhOnco 2025-10-17T09:04Z 3381 followers, 3145 engagements
"🎯 Dato-DXd doubles ORR & improves survival in 1L TNBC 💪🩸 #TROPIONBreast02 Phase III 1L inoperable/metastatic TNBC 💊 Arms: 🔹 Dato-DXd X mg/kg Q3W (n=323) 🔹 Investigators choice chemo (ICC n=321) 📈 Results (BICR): ORR: XXXX% vs XXXX% ( +33%) CR: X% vs XXX% Median PFS: XXXX mo vs XXX mo (HR 0.57) Median OS: XXXX mo vs XXXX mo (HR 0.79) ✅ Takeaway: Dato-DXd significantly improved PFS (+5.3 mo) and OS (+5.0 mo) vs chemo #ESMO25 #OncoTwitter #BreastCancer #TNBC @OncoAlert @myesmo @esmo_open @AnnOncology"
X Link @DrRishabhOnco 2025-10-19T08:33Z 3383 followers, 1188 engagements
"🚀 From local shot ➡ systemic fight: Intratumoral CD40 agonist sparks tumor immunity 🔥 🧬 Cancer Cell Oct 2025 Phase X (NCT04059588) XX pts with metastatic solid tumors 💊 Therapy: Fc-engineered anti-CD40 agonistic antibody 2141-V11 (i.t.) 🎯 Enhances FcRIIB binding better CD40 cross-linking & immune activation 📊 Results ✅ Safe no DLTs up to XX mg dose 💪 Responses in 6/12 pts (2 CR melanoma & HR+ breast cancer) 🌍 Abscopal effect: regression of non-injected lesions 🧫 Mechanism: formation of tertiary lymphoid structures (TLS) local CD8 T-cell priming 🧠 Mouse model: TLS formed long-term"
X Link @DrRishabhOnco 2025-10-15T14:04Z 3383 followers, 1459 engagements
"🔥 Chemo-IO climbs the MATTERHORN Durvalumab + FLOT ⛰ lifts peri-operative gastric/GEJ cancer outcomes at #ESMO25 ✅ OS HR XXXX (p = 0.021) ✅ Higher pCR & EFS gains across PD-L1 + node-positive & diffuse subgroups 💪 Median OS NR in both arms but curves clearly part ways 📊 Durvalumab + FLOT sets a new standard for fit resectable disease. #OncoTwitter #GastricCancer #Immunotherapy #ESMO25 @OncoAlert @myesmo @esmo_open"
X Link @DrRishabhOnco 2025-10-17T19:21Z 3382 followers, 3168 engagements
"🎯 HARMONi-6 delivers new hope in 1L advanced squamous #NSCLC 🫁 📍 Phase III n=532 1L Stage IIIBIV sqNSCLC 💊 Arms: 🔹 Ivonescimab + chemo (20 mg/kg Q3W) 🔹 Tislelizumab + chemo (200 mg Q3W) Followed by monotherapy maintenance 📈 Results: PFS: XXXX mo vs XXX mo (HR XXXX 0.460.78 p0.0001) PD-L1 1%: XXX vs XXX mo (HR 0.55) PD-L1 1%: XXXX vs XXX mo (HR 0.66) ✅ Consistent benefit across subgroups ⚕ Safety: SAE XXXX % vs XXXX % Grade X hemorrhagic events XXX % vs XXX % 🧩 Takeaway: Ivonescimab-chemo shows superior PFS vs tislelizumab-chemo - emerging as a potential new 1L standard for advanced"
X Link @DrRishabhOnco 2025-10-19T00:12Z 3383 followers, 4687 engagements
"🚭 Lung Cancer in Never-Smokers Yes and its rising fast 🫁📈 🧩 Key facts from Murphy et al. JAMA 2025: 15-20% of all lung cancers occur in never-smokers Median age at dx XX y (younger than smokers XX y) 🌏 Rising incidence esp in Asian women (up to XX% cases in Taiwan) 🔬 60-80% adenocarcinoma ⚠ Major risks: passive smoke radon PM2.5 pollution asbestos family hx 🧠 Genomics: 🧬EGFR (43%) & ALK (12%) vs XX% & X% in smokers 🧬Low TMB (03 mut/Mb vs 030) = poorer IO response 💊 Therapy: Adjuvant osimertinib 5-yr OS XX% vs XX% (placebo) Alectinib DFS XX% vs XX% Immunotherapy alone 🪫 limited"
X Link @DrRishabhOnco 2025-10-21T15:32Z 3385 followers, 6188 engagements